Novartis AG
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Vas Narasimhan
- Full Time Employees
- 75,511
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- Lichtstrasse 35 Basel BS Switzerland 4056
- IPO Date
- Nov 7, 1996
- CIK
- 0001114448
- Website
- novartis.com
- Similar Companies
- Business
- Novartis AG (NVS), a Swiss multinational pharmaceutical company headquartered in Basel and founded in 1996 through the merger of Ciba-Geigy and Sandoz, develops, manufactures and markets innovative medicines focused on oncology, immunology, neuroscience, cardiovascular, renal and metabolic diseases; key products include Kisqali (ribociclib) for breast cancer, Cosentyx (secukinumab) for psoriasis and arthritis, Entresto (sacubitril/valsartan) for heart failure, Kesimpta (ofatumumab) for multiple sclerosis, Pluvicto for prostate cancer, Scemblix (asciminib) for leukemia, Leqvio for cholesterol reduction, Zolgensma for spinal muscular atrophy, and radioligand therapies alongside gene and cell therapies like Kymriah (tisagenlecleucel). The company operates globally with major research hubs in Cambridge, Massachusetts, and expanded facilities in the US including a new San Diego research center planned for 2028-2029 and manufacturing investments totaling over $23 billion across 10 sites to achieve 100% end-to-end US production of key medicines by end-2025; it spun off its generics division Sandoz in October 2023 and Alcon eye care in 2019 to sharpen focus on high-value innovative medicines. Recent strategic moves include the October 2025 $12 billion acquisition of Avidity Biosciences to bolster RNA therapeutics for neuromuscular diseases, completion of Tourmaline Bio acquisition for pipeline enhancement, February 2025 purchase of Anthos Therapeutics for $925 million in cardiovascular assets, April 2025 agreement to acquire Regulus Therapeutics for up to $1.7 billion in microRNA therapies, plus licensing deals with Argo Biopharma, Arvinas, Arrowhead Pharmaceuticals and Dren Bio exceeding $17 billion in potential value to offset patent losses and drive 5-6% compound annual sales growth through 2030.
NVS Gains EC Approval for SMA Therapy Itvisma in Broad Population
3 European Stocks to Carry Investors Through the Back Half of 2026
Novartis Eyes $5 Billion Pluvicto Opportunity
Antares Therapeutics signs potential $1.9 billion cancer drug deal with Novartis
Antares Therapeutics Enters Agreement with Novartis to Discover, Develop and Commercialize First-in-Class Cancer Therapies
Biotech's Silent Resurgence (5-Year Base Breakout)
Novartis' Rhapsido Meets Primary Goal in Phase III Skin Disorder Study
Dividend Safety Check: FNDF and International Large-Cap Dividend Income
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
Novartis says rare muscle disease drug shows promise in early trial
Novartis Reports Positive Data for Neuromuscular Disorder Drug
Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines
Novartis' $12 Billion Bet Pays Off With Encouraging Data From Rare Neuromuscular Disease Study
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
Orionis Biosciences Announces Strategic Collaboration with Novartis to Discover and Develop Molecular Glue Medicines
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients